Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer
CLINICAL COLORECTAL CANCER, cilt.18, sa.2, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 2
- Basım Tarihi: 2019
- Doi Numarası: 10.1016/j.clcc.2018.12.004
- Dergi Adı: CLINICAL COLORECTAL CANCER
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Anahtar Kelimeler: Bevacizumab, Biomarker, Colorectal cancer, Neuroendocrine differentiation, Tumor-associated macrophages, PROGNOSTIC-FACTOR, PROGRESSION, BIOMARKERS
- Ankara Üniversitesi Adresli: Evet
Özet
No predictive marker is available for antiangiogenic treatment modalities in routine practice. The present study included a group of patients with advanced colorectal cancer, including 123 consecutive patients treated with bevacizumab plus chemotherapy, to determine the predictive and prognostic role of tumor-associated macrophages (TAMs) and neuroendocrine differentiation (NED) of primary tumor tissue. High TAM infiltration and the presence of NED in tumor tissue were predictors for poor survival.